We are live on ! Find out more
NXTM

NxStage Medical Inc.
NXTM

Delisted

NXTM was delisted on the 21st of February, 2019.

171 hedge funds and large institutions have $1.59B invested in NxStage Medical Inc. in 2018 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 48 increasing their positions, 59 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 24

12% more capital invested

Capital invested by funds: $1.42B → $1.59B (+$168M)

2% more funds holding

Funds holding: 168171 (+3)

4% less call options, than puts

Call options by funds: $1.92M | Put options by funds: $1.99M

13% less funds holding in top 10

Funds holding in top 10: 87 (-1)

19% less repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 59

Holders
171
Holders Change
+3
Holders Change %
+1.79%
% of All Funds
3.91%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.16%
New
28
Increased
48
Reduced
59
Closed
24
Calls
$1.92M
Puts
$1.99M
Net Calls
-$70K
Net Calls Change
-$404K
Name Holding Trade Value Shares
Change
Change in
Stake
HCM
101
Highbridge Capital Management
New York
$1.12M +$1.07M +40,000 New
TMAM
102
Tokio Marine Asset Management
Japan
$1.04M +$998K +37,200 New
BCM
103
BlueCrest Capital Management
Jersey
$984K -$678K -25,274 -42%
BCA
104
Burren Capital Advisors
Gibraltar
$982K
GXMC
105
Global X Management Company
New York
$941K +$904K +33,712 New
MIM
106
MetLife Investment Management
New Jersey
$851K
AC
107
Athos Capital
Hong Kong
$837K -$1.15M -42,777 -59%
PPA
108
Parametric Portfolio Associates
Washington
$735K +$11.6K +434 +2%
VOYA Investment Management
109
VOYA Investment Management
Georgia
$724K -$80.3K -2,996 -10%
Invesco
110
Invesco
Georgia
$694K +$143K +5,339 +27%
LOAMU
111
Lombard Odier Asset Management (USA)
New York
$675K +$649K +24,200 New
NSEDCP
112
NJ State Employees Deferred Compensation Plan
New Jersey
$670K -$536K -20,000 -45%
GC
113
Guggenheim Capital
Illinois
$643K -$4.67K -174 -0.8%
PCM
114
Prelude Capital Management
New York
$642K -$291K -10,842 -32%
Legal & General Group
115
Legal & General Group
United Kingdom
$636K -$122K -4,537 -17%
Two Sigma Investments
116
Two Sigma Investments
New York
$618K -$601K -22,396 -50%
PAM
117
Panagora Asset Management
Massachusetts
$609K -$116K -4,312 -16%
GI
118
GAMCO Investors
Connecticut
$594K -$105K -3,900 -15%
MLICM
119
Metropolitan Life Insurance Company (MetLife)
New York
$586K
KAM
120
Kassirer Asset Management
Ontario, Canada
$558K -$536K -20,000 -50%
T. Rowe Price Associates
121
T. Rowe Price Associates
Maryland
$547K +$145K +5,397 +38%
MTCM
122
Mint Tower Capital Management
Netherlands
$488K +$469K +17,500 New
LCS
123
Levin Capital Strategies
New York
$423K -$362K -13,482 -47%
AG
124
Aperio Group
California
$405K +$18.2K +677 +5%
JG
125
Jefferies Group
New York
$381K -$5.36K -200 -1%

NXTM Hedge Fund Activity: Q2 2018 in Review

171 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in NxStage Medical Inc. (NXTM) for Q2 2018, worth a combined $1.59B — up 12% from $1.42B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new NXTM positions and 24 closed out — a net gain of 4 holders — while 48 added to existing stakes and 59 trimmed.

The largest buyer was TIG Advisors LLC, adding an estimated $47.9M. The largest seller was Pennant Capital Management, cutting an estimated $37.4M.

  • 171 institutional investors held NxStage Medical Inc. (NXTM) as of Q2 2018, up from 168 in Q1 2018.
  • Funds reported $1.59B of NxStage Medical Inc. stock for Q2 2018, up 12% quarter-over-quarter.
  • 28 funds opened new NxStage Medical Inc. positions in Q2 2018 and 24 closed out, a net change of +4 holders.
  • The largest NxStage Medical Inc. buyer in Q2 2018 was TIG Advisors LLC, an estimated $47.9M added.
  • The largest NxStage Medical Inc. seller in Q2 2018 was Pennant Capital Management, an estimated $37.4M sold.

Based on aggregated 13F filings for Q2 2018.